0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Antibody > Bevacizumab > BEB-BY13

Biotinylated Anti-Bevacizumab Antibody (AY13) (recommended for PK/PD)

Order Now

  • Source

    Biotinylated Anti-Bevacizumab Antibody (AY13) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

  • Clone

    AY13

  • Species

    Mouse

  • Isotype

    Mouse IgG1 | kappa

  • Antibody Type

    Hybridoma Monoclonal

  • Reactivity

    Human

  • Immunogen

    Bevacizumab.

  • Specificity

    Recognizes Bevacizumab specifically.

  • Application
    ApplicationRecommended Usage
    ELISA1-100 ng/mL
  • Purity

    >95% as determined by SDS-PAGE.

  • Purification

    Protein A purified / Protein G purified

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
SDS-PAGE
Bevacizumab SDS-PAGE

Biotinylated Anti-Bevacizumab Antibody (AY13) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 Bevacizumab ELISA

Detection of bevacizumab by bridging ELISA in serum. Immobilized Anti-Bevacizumab Antibody (AY10) (Cat. No. BEB-Y10) at 2 μg/mL, add increasing concentrations of bevacizumab (10% human serum) and then add Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) at 2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.4 μg/mL (QC tested).

 Bevacizumab ELISA

Immobilized bevacizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) with a linear range of 0.78-25.5 ng/mL.

 Bevacizumab ELISA

ELISA analysis shows that the binding of bevacizumab to Human VEGF165, premium grade (Cat. No. VE5-H4210) was inhibited by increasing concentration of Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13). The concentration of bevacizumab used is 4 ng/mL.

  • Background
    A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
  • Clinical and Translational Updates

Comments (0)


Voraussichtlicher Liefertermin für vorrätige Produkte: 2 Arbeitstage

Price(USD) : $350.00

Price(USD) : $1520.00

Promotion & Exhibitions



Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Nachricht schicken